Decoding NETosis-associated immune dysregulation in diffuse large B-cell lymphoma through integrative multi-omics and...

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy driven by complex immune dysregulation, yet the role of NETosis, a distinct neutrophil immune effector program, in the tumor immune microenvironment and patient prognosis remains poorly defined. This study leveraged an integrative multi-omics and machine learning framework to elucidate the immunological implications of NETosis-related genes (NETosis-RGs) in DLBCL.

NETosis-RGs were identified from transcriptomic profiles of DLBCL versus control tissues (GSE32018). Prognostic candidates were screened by univariate Cox regression and modeled using five machine learning algorithms, with the Random Survival Forest (RSF) model selected for risk stratification. Bulk and single-cell transcriptomic data were integrated to resolve the immune landscape, while ceRNA networks and m⁶A regulator analyses were performed to characterize post-transcriptional and epigenetic layers. Chemotherapy sensitivity was predicted to explore therapeutic vulnerabilities.

The RSF-based model, incorporating five key NETosis-RGs (AKT1, SLC25A37, FPR2, TLR7, F3), robustly stratified patients into high- and low-risk groups exhibiting systematically distinct immune architectures-spanning differential immune cell infiltration, stromal/immune scores, and immune checkpoint expression. Single-cell transcriptomic analysis further revealed that these prognostic genes were predominantly expressed in monocytes and M1 macrophages and displayed dynamic regulation along myeloid/macrophage differentiation trajectories, suggesting their role as potential modulators of the immunosuppressive-to-inflammatory transition within the DLBCL microenvironment. Complementary analyses revealed multi-layered regulatory mechanisms, including m⁶A modification patterns and lncRNA-miRNA-mRNA ceRNA axes.

By integrating multi-omics data with machine learning, this study delineates a novel NETosis-centered immune signature that refines prognostic stratification and provides mechanistic insights into monocyte/macrophage-mediated immune dysregulation in DLBCL. The findings offer a framework for future immunomodulatory biomarker development and the development of precision therapeutic strategies.